Radiopharm Theranostics (ASX: RAD) has dosed the first patient in its Phase 1 trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 for advanced prostate cancer.
The study will evaluate the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402 in patients with advanced prostate cancer.
In a statement, Riccardo Canevari, CEO and managing director of Radiopharm, commented, “Dosing the first patient in our Phase 1 study of RAD 402 marks an important step forward for Radiopharm and for patients with advanced prostate cancer. RAD 402 is a differentiated, first-in-class, next-generation radiotherapeutic designed to selectively target KLK3-expressing tumors while minimizing off-target exposure.
He added, “With preclinical data demonstrating strong tumor uptake and minimal bone or marrow involvement, we are optimistic about its potential clinical profile. Advancing this program into the clinic reflects our continued commitment to delivering meaningful data across our portfolio this year. I like to take the opportunity to thank our partners, TerThera and Cyclotek, for the great support in supplying Tb161, radiolabelling, and distributing RAD 402.”
